CD274 and non-small cell lung carcinoma: Specifically, immune checkpoint inhibitors (ICIs), which target PD-1 and PD-L1 inhibition, have become a standard second-line treatment for patients with non-small cell lung cancer (NSCLC) after demonstrating a survival advantage over monotherapy with single-agent chemotherapy [5,6,7,8].